Pravalip

/ Unipharm

10-40 mg daily at bedtime.
Response within 1-2 weeks.
Maximal effect is within 4 weeks.
Elderly: Initiate at lower dose and monitor.

As a component of multiple risk intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Should be used in addition to a diet after other nonpharmacological measures alone have been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients without clinically evident coronary heart disease, treatment is indicated to: 1) Reduce the risk of myocardial infarction. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death by non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease, including prior MI, therapy is indicated to: Slow the progression of coronary atherosclerosis; reduce the risk of acute coronary events. Myocardial infarction: In patients with previous myocardial infarction, and normal cholesterol levels, treatment is indicated to: Reduce the risk of recurrent myocardial infarction; reduce the risk of undergoing myocardial revascularization procedures; reduce the risk of stroke or transient ischemic attack (TIA). Hypercholesterolemia and mixed dyslipidemia: Treatment is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb).

Hypersensitivity. Pregnancy. Lactation. Active liver disease or  constant, unexplained elevation in liver function test results.